This company listing is no longer active
KIP Stock Overview
Kolinpharma S.p.A. operates as a nutraceuticals company in Italy. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kolinpharma S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.90 |
| 52 Week High | €10.00 |
| 52 Week Low | €6.98 |
| Beta | 0.65 |
| 1 Month Change | 0% |
| 3 Month Change | -0.50% |
| 1 Year Change | 22.83% |
| 3 Year Change | 22.22% |
| 5 Year Change | 56.47% |
| Change since IPO | 41.65% |
Recent News & Updates
Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital
Jun 17
What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?
Dec 01Recent updates
Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital
Jun 17What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?
Dec 01An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% Undervalued
Aug 25We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt
Jun 08Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?
May 21Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?
May 03Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E Ratio
Apr 13What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?
Feb 20Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Dec 28These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well
Nov 22Shareholder Returns
| KIP | IT Personal Products | IT Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 3.2% |
| 1Y | 22.8% | 1.4% | 16.6% |
Return vs Industry: KIP exceeded the Italian Personal Products industry which returned 7.4% over the past year.
Return vs Market: KIP exceeded the Italian Market which returned 17.6% over the past year.
Price Volatility
| KIP volatility | |
|---|---|
| KIP Average Weekly Movement | 1.1% |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IT Market | 7.6% |
| 10% least volatile stocks in IT Market | 2.6% |
Stable Share Price: KIP has not had significant price volatility in the past 3 months.
Volatility Over Time: KIP's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 107 | Rita Petrelli | www.kolinpharma.com |
Kolinpharma S.p.A. operates as a nutraceuticals company in Italy. The company engages in the development and marketing of food supplements. It provides multivitamins, energizers and dietetics, and drugs.
Kolinpharma S.p.A. Fundamentals Summary
| KIP fundamental statistics | |
|---|---|
| Market cap | €15.91m |
| Earnings (TTM) | €342.34k |
| Revenue (TTM) | €15.62m |
46.5x
P/E Ratio1.0x
P/S RatioIs KIP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KIP income statement (TTM) | |
|---|---|
| Revenue | €15.62m |
| Cost of Revenue | €7.39m |
| Gross Profit | €8.23m |
| Other Expenses | €7.89m |
| Earnings | €342.34k |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 52.71% |
| Net Profit Margin | 2.19% |
| Debt/Equity Ratio | 105.3% |
How did KIP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/01 09:50 |
| End of Day Share Price | 2023/09/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kolinpharma S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luigi Tardella | EnVent Capital Markets Limited |
| Luisa Primi | IR Top Consulting S.r.l. |